Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality worldwide. The disease and its treatments significantly impact patients' quality of life (QoL), including physical, psychological, and social functioning. Patient-Reported Outcome Measures (PROMs) complement clinical assessments. T...
M. Di Nitto, G. Chiloiro, D. D'Angelo et al.· Frontiers in Health Services· 0 citations
Background In resected liver-limited metastatic colorectal cancer (LL-mCRC), disease-free survival (DFS) and postsurgical overall survival (psOS) have been found to be weakly related in heterogeneous retrospective series, challenging the role of DFS as a surrogate biomarker of psOS. Additionally, it remains unclear whe...
M. Germani, A. Taravella, D. Rossini et al.· ESMO Open· 0 citations
BACKGROUND
Adjuvant chemotherapy (ACT) indication in stage II colorectal cancer (CRC) remains challenging, as clinical, pathological, and ctDNA inadequately predict benefit. Immune infiltration correlates with outcome, yet transcriptional signatures have not been systematically evaluated in prospective trial cohorts. W...
A. Puccini, L. Ferrando, G. Frige' et al.· Translational Oncology· 0 citations
CisGem did not statistically improve DFS compared to capecitabine and should thus not be applied as standard of care in the adjuvant setting and should thus not be applied as standard of care in the adjuvant setting.
A. Stein, J. Bridgewater, H. Klümpen et al.· Annals of Oncology· 1 citation
High baseline circulating and tumor γδ T cells and early circulating CD8⁺PD-1⁺ T Cell expansion were associated with better outcome under AtezoBev, and an early induction of T cell-associated interferon-γ signaling at 3 weeks after the first injection of AtezoBev in patients that experienced response.
I. Galy-Fauroux, A. Asif-Laidin, M. Evain et al.· Clinical Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.